Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1995 2
1996 2
1997 2
1998 1
1999 3
2000 5
2001 4
2002 2
2004 1
2005 2
2006 3
2007 1
2008 4
2010 3
2011 2
2012 1
2013 1
2014 2
2015 3
2016 1
2017 1
2018 1
2019 3
2020 3
2021 3
2023 3
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Klencke BJ, Ro S, Donahue R, Kawashima J, Mesa R; MOMENTUM Study Investigators. Verstovsek S, et al. Lancet. 2023 Jan 28;401(10373):269-280. doi: 10.1016/S0140-6736(22)02036-0. Lancet. 2023. PMID: 36709073 Clinical Trial.
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.
Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, Legrand O, Thomas X, Turlure P, Reman O, de Revel T, Gastaud L, de Gunzburg N, Contentin N, Henry E, Marolleau JP, Aljijakli A, Rousselot P, Fenaux P, Preudhomme C, Chevret S, Dombret H; Acute Leukemia French Association. Castaigne S, et al. Lancet. 2012 Apr 21;379(9825):1508-16. doi: 10.1016/S0140-6736(12)60485-1. Epub 2012 Apr 5. Lancet. 2012. PMID: 22482940 Clinical Trial.
Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials.
Verstovsek S, Mesa R, Gupta V, Lavie D, Dubruille V, Cambier N, Platzbecker U, Hus M, Xicoy B, Oh ST, Kiladjian JJ, Vannucchi AM, Gerds A, Egyed M, Mayer J, Sacha T, Kawashima J, Morris M, Huang M, Harrison C. Verstovsek S, et al. Among authors: cambier n. Blood Adv. 2023 Jul 25;7(14):3582-3591. doi: 10.1182/bloodadvances.2022009311. Blood Adv. 2023. PMID: 37042865 Free PMC article.
Chronic Myelomonocytic Leukemia Patients With Lysozyme Nephropathy and Renal Infiltration Display Markers of Severe Disease.
Lafargue MC, Bobot M, Rennke HG, Essig M, Carre M, Mercadal L, Farhi J, Sakhi H, Comont T, Golbin L, Isnard P, Chemouny J, Cambier N, Laribi K, Selamet U, Riella LV, Fain O, Adès L, Fenaux P, Cohen C, Mekinian A; MINHEMON, GFM and French VEXAS group. Lafargue MC, et al. Among authors: cambier n. Kidney Int Rep. 2023 Sep 7;8(12):2733-2741. doi: 10.1016/j.ekir.2023.09.005. eCollection 2023 Dec. Kidney Int Rep. 2023. PMID: 38106568 Free PMC article.
[Iron overload and myelodysplastic syndromes].
Rose C, Cambier N, Mahieu M, Ernst O, Fenaux P. Rose C, et al. Among authors: cambier n. Transfus Clin Biol. 2001 Oct;8(5):422-32. doi: 10.1016/s1246-7820(01)00193-8. Transfus Clin Biol. 2001. PMID: 11729396 Review. French.
Chronic myelomonocytic leukemia: from biology to therapy.
Cambier N, Baruchel A, Schlageter MH, Menot ML, Wattel E, Fenaux P, Chomienne C. Cambier N, et al. Hematol Cell Ther. 1997 Apr;39(2):41-8. doi: 10.1007/s00282-997-0041-4. Hematol Cell Ther. 1997. PMID: 9168299 Review.
[Pregnancy and essential thrombocytemia].
Giraudet G, Wibaut B, Ducloy AS, Deruelle P, Depret S, Cambier N, Vaast P, Houfflin-Debarge V. Giraudet G, et al. Among authors: cambier n. Gynecol Obstet Fertil. 2011 Apr;39(4):205-10. doi: 10.1016/j.gyobfe.2011.01.017. Epub 2011 Mar 29. Gynecol Obstet Fertil. 2011. PMID: 21450510 French.
Familial myeloid malignancies with germline TET2 mutation.
Duployez N, Goursaud L, Fenwarth L, Bories C, Marceau-Renaut A, Boyer T, Fournier E, Nibourel O, Roche-Lestienne C, Huet G, Beauvais D, Berthon C, Cambier N, Quesnel B, Preudhomme C. Duployez N, et al. Among authors: cambier n. Leukemia. 2020 May;34(5):1450-1453. doi: 10.1038/s41375-019-0675-6. Epub 2019 Dec 11. Leukemia. 2020. PMID: 31827242 No abstract available.
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.
Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, Sarlis NJ, Peng W, Sandor V, Gopalakrishna P, Hmissi A, Stalbovskaya V, Gupta V, Harrison C, Verstovsek S; COMFORT Investigators. Vannucchi AM, et al. Haematologica. 2015 Sep;100(9):1139-45. doi: 10.3324/haematol.2014.119545. Epub 2015 Jun 11. Haematologica. 2015. PMID: 26069290 Free PMC article. Clinical Trial.
Acute myocarditis induced by hypomethylating agents.
Bibault JE, Cambier N, Lemahieu JM, Quesnel B, Auffret M, Rose C. Bibault JE, et al. Among authors: cambier n. J Clin Oncol. 2011 May 10;29(14):e411-2. doi: 10.1200/JCO.2010.33.4656. Epub 2011 Feb 28. J Clin Oncol. 2011. PMID: 21357777 No abstract available.
57 results